SAT-LB113 Psychosocial Benefits of Using Basal-IQ® Predictive Low Glucose Suspend Technology in a Real-World Setting: Results From Pediatric Patients With Type 1 Diabetes

Recent literature has highlighted remarkable clinical benefits of the Basal-IQ PredictiveLow Glucose Suspend (PLGS) technology for both pediatric and adult patients with type 1diabetes (PwT1D). Although less frequently acknowledged in the literature, psychosocial benefits and other patient-reported outcomes (PROs) related to this technology, are critical to its sustained and satisfactory use. For purposes of this study, we analyzed pediatric PwT1Ds (n=123) who had recently started using the t:slim X2 insulin pump with Basal-IQ technology (Tandem Diabetes Care). These pediatric users were part of a larger recruited sample that also included adults with T1D (not described here). Amongst other clinical and demographic measures, pediatric PwT1Ds completed the Diabetes Impact and Device Satisfaction (DIDS) scale at baseline and then again at 6 months post-assessment(PA). The DIDS is a brief, reliable, and validated measure to ascertain device-specific satisfaction as well as impact of diabetes management in PwT1D. Pre-Post differences on DIDS were analyzed using repeated measures analysis of variance. Mean age of the pediatric sample was 12.25 years, female=45%, mean HbA1c=7.62%. At baseline, 91%used CGM, 27% used multiple daily injections, and 73% used insulin pumps as their therapy method. Parents/caregivers completed the DIDS on behalf of their child in most cases (92%). At PA, pediatric PwT1Ds, demonstrated significant changes on both subscales of the DIDS. Significant improvements were observed for device-related satisfaction (DS) (p<.001) whereas significant reduction was noted for diabetes-related impact (DI) (p<.01) indicating reduced burden of diabetes on daily life. These findings were noted regardless of patients’ baseline insulin delivery methods (MDI or insulin pump). For DS, at PA, patients reported the most improvement on items relating to“satisfaction with insulin delivery device” (29% increase, p<.001) and “hassle to use” (58%decrease, p<.001). For DI, items indicating the most reduction of diabetes impact were“worry about going low” (36% decrease, p<.001) and “wake up at night to treat low BG”(27% decrease, p<.001). These findings highlighted robust real-world evidence for psychosocial benefits of Basal-IQ technology for pediatric patients and their parents/caregivers. Using psychosocial PROs while evaluating medical devices and technologies is critical as they improve our understanding of patients’ experiences with these systems and their impact on quality of life. These aspects may not always be reflected in patients’ clinical outcomes but are essential for determining long term use and acceptance of new treatments and management regimens.